Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.49M$5.49Mderived+254.4% vs Q4 2024 Net Income-$15.53M-$15.53MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$14,781,000N/M Operating Cash Flowderived-$17,233,000N/M Free Cash Flowderived-$17,233,000N/M Margins · derivedOperating margin-269.1%+1843.0 pt vs Q4 2024
Net margin-282.7%+1895.7 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 5, 2026 · 64 d after period end